27 results about "Reduced appetite" patented technology

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention belongs to the technical field of traditional Chinese medicine, and in particular to a Chinese medicine composition for treating depression. The Chinese medicine composition is mainly prepared from astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, kudzu root, angelica, salvia miltiorrhiza, honeysuckle, seaweed, kelp, oyster, and immature bitter orange. The Chinese medicine composition of the present invention can significantly improve the symptoms of loss of appetite and weight loss in depression model rats, improve the symptoms of loss of interest in depression model rats, effectively alleviate the symptoms of increased inflammatory factors TNF-α, IL-1β, and INF-γ caused by depression, significantly increase the levels of 5-hydroxytryptamine and dopamine in rat cortex and hippocampus, and effectively treat depression.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention discloses an application of bifidobacterium animalis subsp. Lactis SS9 in preparation of a product for preventing and treating stress obesity. The bifidobacterium animalis subsp. Lactis SS9 obtained by screening can remarkably relieve obesity induced by combination of chronic pressure and high-fat diet, and the obesity is represented by slowing down weight increase, reducing appetite, improving blood fat, up-regulating GLP-1 and insulin secretion and effectively relieving anxiety-like and depression-like behaviors. Researches find that the strain can regulate the hypothalamic-pituitary-adrenal axis activation level, improve secretion imbalance of hormones such as CRH, ACTH and CORT, restore expression of appetite regulation factors such as NPY / AgRP / POMC of hypothalamic and relieve emotional eating behaviors. In addition, the strain can also reduce the systemic inflammation level, recover the diversity of intestinal flora and improve the proportion of beneficial bacteria. The invention provides the probiotics with multiple effects of regulating emotion, controlling body weight and improving metabolic disorder, and a new strategy is provided for preventing and treating stress-related obesity.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

The invention provides a composition comprising the following components: a hydrogel material, monovalent or divalent cation salt, a filler, a disintegrating agent and a lubricant. The composition is scientific and reasonable in formula combination, free of toxic and side effects on human bodies and easy to prepare. The product prepared from the composition disclosed by the invention can simultaneously have good preparation performance, disintegration performance and gelling performance through specific components, proportion and preparation process, is relatively high in stability of product quality, is suitable for large-scale application and development, and can occupy the space in the stomach, promote satiety and reduce appetite after being eaten; therefore, the purposes of weight management, obesity treatment, blood sugar control, diabetes prevention and treatment, blood cholesterol reduction and the like are achieved.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures thereof, a crosslinking compound, a foaming agent, and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, an acid selected from tartaric acid, succinic acid, ascorbic acid, and mixtures thereof. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The present invention primarily relates to a combination agent for reducing appetite and / or for providing a feeling of satiety and / or for reducing energy intake and / or for reducing body weight. In addition, the present invention relates to a medical use of the combination agent, in particular for the treatment of overweight and obesity and for the prevention of cardiovascular disease, stroke, diabetes, and joint damage and wear of the spine, and to a non-therapeutic use of the combination agent. In particular, the focus of the present invention is on the use of the combination agent to provide a feeling of satiety and / or to reduce energy intake and / or to reduce body weight. Finally, the present invention relates to the use of the combination agent for the preparation of an orally consumable preparation or food ingredient and an orally consumable preparation or food ingredient prepared therefrom.

The invention discloses a composite liver and kidney protective agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The protective agent is prepared from 10%-20% of inosine, 15%-25% of glutamic acid, 10%-15% of cysteine, 15%-20% of glycine, 5%-10% of a coenzyme compound, 10%-20% of small molecule peptide and auxiliary materials. The preparation method comprises the steps of premixing, low-temperature homogenization, spray drying and preparation forming, and uniform distribution of components is ensured through a spray drying technology. The traditional Chinese medicine composition plays a role through a three-stage mechanism of fat removal, repair and regeneration, reduces lipid deposition, scavenges free radicals, repairs hepatocytes and promotes regeneration. The traditional Chinese medicine composition can be used for treating or preventing liver and kidney diseases such as non-alcoholic fatty liver, viral hepatitis and cirrhosis, relieving symptoms such as anorexia, jaundice and bleeding, dispelling the effects of alcohol, protecting the liver and enhancing immunity. The proportion of natural components of the protective agent is more than 80%, the safety is high, multiple targets are synergistic, and the curative effect is superior to that of a single-component medicine.

The invention discloses application of leuconostoc mesenteroides and / or metabolites of the leuconostoc mesenteroides to preparation of a composition for reducing body fat, reducing appetite, promoting ketone mass or regulating fasting blood glucose, wherein the leuconostoc mesenteroides is leuconostoc mesenteroides subsp. Mesenteroides with the preservation number of DSM34443.

This invention discloses a strain of *Drugella*, its produced polysaccharide, and its applications. The *Drugella* G3 strain of this invention has the preservation number CCTCC NO: M 2024137. Its extracellular polysaccharide TDG3, as a TLR4 / DC-SIGN dual receptor agonist, exhibits a significant effect in reducing body weight. The extracellular polysaccharide TDG3 of this invention can significantly reduce appetite, decrease food intake, reduce body weight, and reduce adipose tissue content in mice. It can also alleviate or prevent obesity-induced hepatic steatosis. It is safe and non-toxic, suitable for preparing lipid-lowering and weight-loss drugs, and has good clinical application value and broad application prospects.

Compositions comprising fatty acid analogs are provided for treating conditions involving impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, and convulsion, and other conditions. Methods for the diagnosis and monitoring of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, convulsion, and other conditions are also provided.

The invention relates to the technical field of medical health, in particular to a method for constructing a fat-sweet and cold type functional dyspepsia mouse model, successfully constructs a functional dyspepsia mouse model capable of simulating a high-fat and cold diet mode in modern society, and overcomes the defect that an existing model only depends on a single diet factor. The model not only can effectively simulate the symptoms of the functional dyspepsia, such as anorexia, gastric emptying delay, intestinal tract propulsion function decline and the like, but also can provide a new perspective for further researching the pathogenesis of the functional dyspepsia in combination with the dyspepsia theory of traditional Chinese medicine.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexylamine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

Compositions comprising fatty acid analogs are provided for treating conditions involving impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, and convulsion, and other conditions. Methods for the diagnosis and monitoring of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, convulsion, and other conditions are also provided.

The invention discloses a hydrogel composition with a lipid-lowering effect and a preparation method thereof, and aims to solve the technical problems that the appetite cannot be reduced, the food intake cannot be controlled, a human body cannot be full of vigor and the bactericidal ability is relatively poor due to the fact that an eater cannot have a lasting satiety by a current hydrogel composition. Comprising the following raw materials in percentage by weight: 55-75% of natural dietary fibers, 10-20% of natural dietary fibers and 10-20% of natural dietary fibers. 10-20% by mass of a ginseng extract; 8-14% by mass of vitamin C; 4-7% by mass of a prune extract; 5-9% by mass of a green plum extract; the mass percentage of the potato extract is 3-5%. The hydrogel composition prepared by the preparation method disclosed by the invention can fill the stomach, stimulate the stomach wall and generate lasting satiety through combination of the natural dietary fibers and the potato extract, contributes to reducing appetite and controlling food intake, and can effectively reduce caloric intake and help people to control body weight by increasing the satiety.

The present invention relates to GDF15 analogs and methods for reducing body weight and / or reducing food intake. In particular, the present invention relates to fusion proteins comprising a half-life prolonging protein, a linker and a GDF15 protein, which fusion proteins are useful as GDF15 agonists. These GDF15 agonists are useful for treating obesity, reducing body weight, reducing food intake, or reducing appetite.

The present invention relates to a functional composition for improving the appetite of people in plateaus, the functional composition comprising inulin, codonopsis polysaccharide and bifidobacterium. Experiments show that under the conditions of rapid plateau environment, the combination of these three functional factors can increase the relative abundance of beneficial bacteria such as bifidobacteria in the intestines of mice, and the relative abundance is significantly higher than that of the original control group (P < 0.05), fully exerting the role of regulating intestinal flora; and the synergistic effect of the three functional factors can affect the secretion of appetite hormones and food intake of mice, and has the effect of improving the appetite of people in rapid plateaus. Among them, the appetite-improving effect of the medium- and high-dose inulin group, the low-dose codonopsis polysaccharide group, and the low-dose bifidobacterium group is the most significant. The PYY concentration in the serum of the test group of the composition decreased, and the NPY concentration increased, which alleviated the reduced energy intake and weight loss caused by loss of appetite, and had the functional effect of regulating intestinal flora and improving the appetite of people in rapid plateaus.

The purpose of the present invention is to provide a novel TRPA1 agonist. The present invention relates to a composition for activating TRPA1, comprising a mushroom extract or lanthionine. The composition can enhance appetite and food consumption and ameliorate decreased appetite.

A postbiotic preparation of Pediococcus acidilactici (P. acidilactici), for use in preventing and / or treating obesity, in reducing body fat, in preventing fat accumulation, in reducing appetite, in reducing food intake, or in preventing weight gain.

The invention discloses a probiotic composite beverage with a weight losing function and a preparation method thereof, and belongs to the technical field of probiotic beverages, the method comprises the following steps: raw material pretreatment and modification, fermentation system construction, fermentation, filtration and concentration, synergistic auxiliary material preparation, prebiotic solution preparation, microbial inoculum preparation and mixing. Through cooperation of various probiotics, on one hand, intestinal flora balance is adjusted, harmful bacterium growth is inhibited, the number of beneficial bacteria is increased, the intestinal micro-ecological environment is optimized, chronic inflammatory response caused by endotoxin entering blood is reduced, and the obesity risk related to inflammation is reduced; on the other hand, by influencing fat metabolism and sugar metabolism, fat accumulation is reduced, the blood sugar level is reduced, energy consumption is increased, intestinal tracts are stimulated to generate satiety signals, appetite is reduced, caloric intake is reduced, short-chain fatty acid can be generated, fat metabolism is influenced, and therefore the weight losing effect is achieved.

Ascites and pleural effusion are common complications, and clinical interventions primarily based on symptomatic treatment often result in poor prognoses. Guided by the new theory of "inflammation-cancer" transformation, this invention discloses a traditional Chinese medicine composition for the prevention and treatment of ascites and pleural effusion, along with its preparation methods for internal and external use. The composition comprises the following medicinal materials in parts by weight: Codonopsis pilosula 3-20 parts, Atractylodes macrocephala 3-20 parts, Cinnamomum cassia 3-18 parts, Trichosanthes kirilowii 3-18 parts, Panax notoginseng 3-12 parts, Lobelia chinensis 3-15 parts, Polygonum bistorta 3-15 parts, Euphorbia helioscopia 3-15 parts, and Lepidium apetalum 3-15 parts. This traditional Chinese medicine composition possesses the effects of strengthening the body's resistance, removing blood stasis, detoxifying, eliminating dampness, promoting diuresis, and reducing swelling. It is effective in preventing and treating inflammatory and malignant ascites and pleural effusion, as well as the associated symptoms such as dyspnea, chest pain, cough, loss of appetite, abdominal pain, abdominal distension, fatigue, and night sweats. It can be prepared as a decoction, granules, pills, capsules, or powder. This invention helps promote the absorption and drainage of pleural and peritoneal effusions, reduce inflammation and fight cancer, adjust and restore the physiological functions of internal organs, and improve the quality of life of patients.

Use of Leuconostoc mesenteroides in preparing compositions for reducing body fat, decreasing appetite, promoting ketone production or regulating fasting blood glucose is provided, where the Leuconostoc mesenteroides is Leuconostoc mesenteroides subsp. and the Leuconostoc mesenteroides was deposited at Food Industry Research and Development Institute under the accession number BCRC911146 or German Collection of Microorganisms and Cell Cultures under the accession number DSM34443.